WALTHAM, MA– Axial Biotherapeutics, a biotechnology company announced the appointment of Scott Brun M.D. to its Board of Directors.
In addition, the Company announced the promotions and expanded roles of Stewart Campbell, Ph.D., to Senior Vice President and Head of R&D, Chris Meyer to Vice President of Operations and Hitesh Bhagat, Ph.D., as Vice President, Drug Delivery and Chemistry, Manufacturing and Controls (CMC).
Mr. Bhagat is a seasoned bio/pharmaceutical executive with 30 years of experience in full life-cycle of product development. He has led/participated in more than 35 drug product/device developments, including Renagel®, Welchol® and Renvela at Genzyme.
Prior to his industry experience, Mr. Bhagat was a tenure track faculty member at the University of Maryland and before that, worked on biodegradable delivery systems in Dr. Langer’s lab. He holds several patents, has authored/co-authored 50 abstracts/publications and 2 book chapters.
Mr. Bhagat holds a PhD from the Massachusetts College of Pharmacy and a Diploma in Business Management from the Bombay University.
“We are excited with the progress we have made on our Autism Spectrum Disorder and Parkinson’s Disease programs in such a short period of time. As we continue to advance our programs and build out our operational and clinical capabilities, we are pleased to add Dr. Scott Brun to our Board of Directors, an industry veteran with over two decades of drug and corporate development experience who will be instrumental in advising us on our near-term progress and future development activities,” said David H. Donabedian, Ph.D., CEO of Axial Biotherapeutics.
